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Abstract: The need for competent in vitro liver models for toxicological assessment persists.
The differentiation of stem cells into hepatocyte-like cells (HLC) has been adopted due to its human
origin and availability. Our aim was to study the usefulness of an in vitro 3D model of mesenchymal
stem cell-derived HLCs. 3D spheroids (3D-HLC) or monolayer (2D-HLC) cultures of HLCs were
treated with the hepatotoxic drug nevirapine (NVP) for 3 and 10 days followed by analyses of Phase I
and II metabolites, biotransformation enzymes and drug transporters involved in NVP disposition.
To ascertain the toxic effects of NVP and its major metabolites, the changes in the glutathione net
flux were also investigated. Phase I enzymes were induced in both systems yielding all known
correspondent NVP metabolites. However, 3D-HLCs showed higher biocompetence in producing
Phase II NVP metabolites and upregulating Phase II enzymes and MRP7. Accordingly, NVP-exposure
led to decreased glutathione availability and alterations in the intracellular dynamics disfavoring
free reduced glutathione and glutathionylated protein pools. Overall, these results demonstrate
the adequacy of the 3D-HLC model for studying the bioactivation/metabolism of NVP representing
a further step to unveil toxicity mechanisms associated with glutathione net flux changes.
Keywords: hepatocytes; nevirapine; stem cells; 3D culture; glutathione; metabolism
1. Introduction
The well-known drawbacks of primary hepatocytes and hepatic cell lines regarding long-term
metabolic stability and competence has prompted efforts for the development of more reliable in vitro
hepatotoxicity models [1]. From those efforts, the differentiation of human iPSCs (induced pluripotent
stem cells), ESC (embryonic stem cells) or hMSC (mesenchymal stem cells) into hepatocyte-like cells
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(HLC) have shown promising results. While various systems have been established to study liver
pathology and toxicity, these models still lack some key liver-specific functionalities, and none of them
has yet been validated for routine hepatotoxicity testing [2] which is of paramount importance to
address drug-induced liver injury (DILI). Importantly, for proper benchmarking of in vitro liver-models
it is crucial the definition of a set of consensus criteria, comprising critical elements such as cell viability,
morphology, functionality and toxicological characterization, as proposed by Vinken and Hengstler [3].
Our team has previously established an improved hepatic differentiation protocol for deriving
HLCs from human neonatal MSCs (hnMSCs) under 2D culture conditions [4]. The hepatic phenotype
of the HLCs was confirmed by an unbiased whole genome analysis that placed the HLCs between
human primary hepatocytes (hpHep) and HepG2, and distant from hnMSCs. Notably, the resort to
spheroid or to multicompartment membrane bioreactor cultures further improved HLC maturation
and functionality [5]. Indeed, three-dimensional (3D) culture systems allow higher cell-to-cell
and cell-to-matrix contact, as well as nutrient and oxygen gradients and cell polarization [6–9]. These
features are essential for the functional specialization of hepatocytes, which can be of enormous impact
when employing in vitro systems to investigate susceptibility to drug-induced adverse-reactions [1],
such as those induced by the hepatotoxic drug nevirapine (NVP), a non-nucleoside reverse transcriptase
inhibitor [6]. In this sense, 3D stem cell-derived hepatic models may be promising tools for the early
assessment of new molecules efficacy or detection of their potential toxic effects, with higher accuracy
and decreased number of sacrificed animals [5,9,10].
Glutathione, a γ-glutamyl-L-cysteinyl-glycine tripeptide, is the most abundant intracellular
antioxidant system, with functions such as cysteine reserve, participation in redox signaling and,
most importantly, in metabolism and detoxification of xenobiotics and endogenous compounds [11].
Glutathione facilitates the plasma membrane transport of metabolites by different mechanisms, the most
important of which is the formation of glutathione S-conjugates. However, glutathione conjugation
reduces its availability and may compromise its normal functions. For glutathione production,
the enzyme glutamate-cysteine ligase (GCL) binds glutamate and cysteine in a rate-limiting step of
the synthetic pathway. This dipeptide is then covalently linked to glycine generating glutathione.
Glutathione can be present in the reduced (GSH) and oxidized (GSSG) free forms or generate
S-glutathionylated proteins upon post-translational modification (GSSP). The GSH/GSSG redox couple
has the essential function of allowing reversible glutathionylation of proteins [12] and GSSP also
prevents irreversible protein inactivation under oxidative stress insults, playing an important role
regarding adaptive responses to drug-induced hepatotoxicity [13].
As mentioned above, NVP is an antiretroviral drug associated with severe hepatotoxicity, through
the formation of reactive metabolites (Figure 1) [7]. NVP biotransformation comprises the formation
of multiple Phase I metabolites (2-, 3-, 8-, and 12-OH-NVP, and 4-carboxy-NVP) that undergo
subsequent Phase II glucuronidation or undergo detoxification trough GSH conjugation (Figure 1) [14].
NVP bioactivation pathways have also been proposed, namely the SULT1A1-mediated Phase II
sulfonation of 12-OH-NVP to 12-sulfoxy-NVP; and the formation of NVP quinone methide from NVP,
12-OH-NVP and 12-sulfoxy-NVP. The reactive electrophilic metabolite NVP quinone methide has been
proposed to be involved in the onset of NVP-induced liver toxicity through formation of covalent
adducts with key proteins (Figure 1) [15]. Besides its extensive metabolism through Phase I and II
enzymes, NVP has also the capability for induction of its own metabolism [14]. Indeed, NVP induces
CYP2B6 and CYP3A4 [16], whereas its Phase I metabolite, 2-OH-NVP (Figure 1), induces SULT1A1 [6].
Therefore, due to its bioactivation, and subsequent detoxification and toxicity mechanisms, NVP has
been shown to be a relevant drug for investigating drug metabolism and bioactivation competence of
in vitro models [6,7].
In this context, we aimed a step forward and propose a novel integrated assessment of NVP
metabolism coupled with the glutathiolomic profile to unveil the suitability of a human HLC 3D model
as an alternative in vitro tool for human metabolism studies, and therefore appropriate for investigating
mechanisms of DILI. To evaluate the competence of this model, we analysed (i) the formation of NVP
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metabolites, its effect on (ii) gene expression of CYPs and (iii) activity of Phase I and Phase II enzymes
and hepatic transporters and its (vi) glutathiolomic profile, over long-term cultures.
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Figure 1. Schematic representation of Nevirapine (NVP) biotransformation and toxic
metabolites formation.
2. Results
2.1. NVP Modulates Key Biotransformation Enzyme Activity in 2D and 3D HLC Cultures
The formation of the major NVP metabolite, 12-OH-NVP, is credited mostly to CYP3A4, but also to
CYP2D6 and CYP2C9 (Figure 1) [16]. On the other hand, the formation of 2-OH-NVP and 3-OH-NVP
is exclusively mediated by CYP3A and CYP2B6, respectively, whereas the conversion to 8-OH-NVP
is attributed to a group of subfamilies that include CYP3A4, CYP2B6 and CYP2D6 (Figure 1) [16].
Therefore, to evaluate the biotransfor ation competence of the HL s, the expression level of genes
relevant for NVP metabolism, as well as Phase I and II activities and corresponding NVP metabolites
were assessed in the cultures treated with NVP for 3 (D27) and 10 days (D34) (Figure 2). The
concentration of 300 µM was used in this study after confirming the absence of cytotoxic effects in
HLCs in all tested endpoints (data not shown).
As shown i Table 1 and in Figure 3, Phase I and II activities were higher in 3D-HLCs when
compared to 2D-HLCs, except for ECOD activity (7-ethoxycoumarin O-deethylation, covering CYP2B6,
1A1/2 and 2E1 [17]) at D27. In particular, CYP3A4/5 activity was induced 5-fold and 1.5-fold in
3D-HLC cultures at D27 and D34, respectively; whereas 2D-HLC cultures showed a ~1.5-fold induction
at both time points (Figure 3). In 3D-HLC cultures, ECOD activity also showed a 1.3-fold and 3.7-fold
induction after 3 (D27) and 10 days (D34) of treatment with NVP, respectively. Conversely, monolayer
cultures only displayed ECOD induction (2.5-fold) at 3 days after treatment (Figure 3). CYP2D6 gene
expression level was slightly increased upon NVP treatment (Figure 2A). In line with these findings,
the levels of NVP Phase I metabolites, together with the corresponding Phase I gene expression, were
also elevated in 3D-HLCs (Figure 4). The conversion of NVP into 2-OH-NVP (total fraction) was
superior in 3D-HLCs (Figure 4). Moreover, the formation of 12-OH-NVP (total fraction) was enhanced
in both cultures from D27 to D34 (Figure 4). The amount of 3-OH-NVP duplicated from D27 to D34 in
3D-HLCs, whereas, as expected, the NVP minor metabolite, 8-OH-NVP, was barely detected in our
systems (Figure 4A).
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Figure 2. Gene expression analyses of Phase I, II and III related genes of 3D- and 2D-HLCs after 3 (D27)
and 10 days (D34) of NVP treatment. (A) Gene expression of Phase I enzymes comprising CYP3A4,
CYP2B6 and CYP2D6 in NVP-treated cells relative to non-treated cells. (B) Gene expression of Phase II
enzymes comprising SULT1A1, UGT1A1 and GSTA1-A2 in NVP-treated cells relative to non-treated
cells. (C) Gene expression of the MRP7 transporter in NVP-treated cells relative to non-treated cells.
(A–C) Data for hnMSC exposed to NVP for 3 days and used as negative controls, are also shown.
(D) Phase I, II and III gene expression in 3D-HLCs relative to 2D-HLCs in NVP-treated cells at D27
and D34. The data (Mean ± SD, n = 3) are normalized to the reference gene β-ACTIN and expressed as
the log10 of the ratios.
Regarding Phase II metabolism and transporters expression levels, the 3D-HLCs cultures showed
an improved performance s well. UGT1A1, SULT1A1, GSTA1-A2 and MRP7 overexpression was
only obs rved in 3D-HLCs (Figure 2B–D). UGT activity and the glucuronic aci conjugates increased
from D27 to D34 in 3D-HLCs (Figure 3), where s no conjugates were detectabl in 2D-HLCs at D34
(Figure 4A). SULT activity improved in both cul ur systems over time (Figure 3), re ulting in increased
production of 3 and 8-OH-NVP sulfate conjugates (Fig re 4A).
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Figure 3. Phase I and Phase II enzymatic induction in 3D- and 2D-HLCs after 3 (D27) and 10 days (D34)
of NVP treatment. The data for hnMSC, cultured in monolayer and exposed to NVP for 3 days, are
presented as negative control. * p < 0.05 and *** p < 0.001 relative to 2D-HLCs, $ p < 0.05 and $$$ p < 0.001
relative to non-treated and ### p < 0.001 relative to D27 of culture. The data (Mean ± SD, n = 3) are
represented as fold induction in NVP-treated cells relative to non-treated cells.
Figure 4. Cont.
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Figure 4. (A) Levels of NVP Phase I and II metabolites in 3D- and 2D-HLCs after 3 (D27) and 10 days
(D34) of NVP treatment. hnMSC cultured in monolayer and exposed to NVP for 3 days are also shown
and (B) relative proportions of total NVP metabolites (free metabolites + sulfate conjugates + glucuronic
acid conjugates) at D27 and D34. The data (Mean ± SD, n = 3) are normalized to total cell number.
Table 1. Comparative summary of 3D- and 2D-HLC metabolic capacity upon 10 days of NVP treatment (D34).
Endpoint a
3D-HLC
(NVP Treated/
Non-Treated)
2D-HLC
(NVP Treated/
Non-Treated)
3D-HLC/
2D-HLC
(NVP Treated)
Gene
expression
Phase I
CYP3A4 + + +
CYP2B6 +++ unchanged +++
CYP2D6 + + +
Phase II
SULT1A1 + unchanged ++
UGT1A1 + unchanged +++
GSTA1-A2 + unchanged ++
Phase III MRP7 + unchanged ++
Enzymatic
activity
Phase I
ECOD ++ unchanged +
CYP3A4 unchanged unchanged unchanged
Phase II
UGTs unchanged unchanged +
SULT1A1 unchanged unchanged unchanged
NVP
metabolites b
Phase I
2-OH-NVP detected detected +
(CYP3A4)
12-OH-NVP detected detected +
(CYP3A4/2D6/2C9)
3-OH-NVP detected detected ++
(CYP2B6)
8-OH-NVP detected detected unchanged
(CYP3A4/2D6/2C9)
Phase II
Sulfate conjugates detected detected ++
Glucuronic acid
conjugates detected not detected +++
Glutathiolomic profile GSH synthesis residual residual +
GSH catabolism + ++ −
a Gene expression: (+) 1–20-fold increase, (++) 20–250-fold increase, (+++) >250-fold increase; Enzymatic activity,
NVP metabolites and glutathione content: (−) <1-fold decrease; (+) 1–4-fold increase; (++) 4–10-fold increase; (+++)
>10-fold increase. b Detected/not detected: production of nevirapine metabolites in nevirapine-treated cultures.
Overall, NVP induced the expression and the activity of the enzymes responsible for its own
metabolism, particularly in 3D culture conditions (Table 1). The longer treatment period allowed us to
cover the induction period of NVP. This is confirmed by the relative proportions of metabolites in both
systems (2-OH-NVP > 12-OH-NVP > 3-OH-NVP > 8-OH-NVP) and its trend to decrease the levels
of 2-OH-NVP and increase the levels of 12-OH-NVP with the time of culture (Figure 4B). Moreover,
the same trend has been observed in an additional timepoint (D31, data not shown).
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2.2. HLC 3D Cultures Are More Efficient in Maintaining the Dynamics of Glutathione Pools
Considering the role of GSH in detoxification of xenobiotics and/or their metabolites, we aimed to
study the HLCs’ glutathione metabolism at different time points to further evaluate cells’ capacity to
adjust to drug exposure. Herein, the glutathiolomic profiling in non-treated cells was firstly performed
in order to compare basal glutathione net flux in 2D and 3D models.
Total intracellular availability was quantified as the sum of contributions of the pools (free reduced
(GSH) plus free oxidized (GSSG) and protein bound (GSSP)). This strategy allowed us to disclose
basal intracellular availability of glutathione and its precursors (Figure 5A). Likewise, we clarified
the intracellular dynamics of glutathione pools between free form (GSH + GSSG) and in the form of
S-glutathionylated proteins (GSSP) (Figure 5B).
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In 2D-HLCs model, culture time (from D27 to D34) resulted in an increase in the intracellular
cysteine levels and decreased GSSP (Figure 5). This may indicate that 2D cells might be striking to
maintain intracellular reduced glutathione levels. The increase in cysteine level in 2D-HLCs was not
followed by an increase in glutathione availability (Figure 5A), neither by increased formation of its
precursor GluCys (Figure 5A). Therefore, the slight increase of intracellular free glutathione availability
at D34 might not only be at the expense of decreasing GSSP (Figure 5B) to compensate for the incapacity
of maintained glutathione synthesis over time (Figure 5A), but rather due to a decrease in gluthathione
excretion at this timepoint (Figure 5A).
Finally, we determined the ratios of glutathione synthesis and extracellular catabolism (see CTRLs,
Figure 6A). Culture time resulted in a shift from glutathione production to catabolism from D27 to D34
in 2D-HLCs (Figure 5A). In 3D-HLCs, on the other hand, the equilibrium GSH synthesis/catabolism is
maintained more stable independently of the time in culture (there is no inter-day variability).
The intracellular availability of GSH precursors and the distribution of GSH between its free
and protein bound forms were maintained, which supports 3D-HLCs as a more relevant model
to study the drug-induced glutathiolomic profile.
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Figure 6. Glutathiolomic analysis of 3D- and 2D-HLCs treated or non-treated with NVP. (A) Effect
of NVP on glutathione synthesis and degradation ratios, after 3 (D27) and 10 days (D34) of NVP
treatment; (B) Effect of NVP on total intracellular availability for cysteine (Cys), glutamylcysteine
(GluCys) and glutathione and total extracellular levels of cysteinylglicine (CysGly) and glutathione,
in 3D-HLCs, after 3 (D27) and 10 days (D34) of NVP treatment; (C) NVP effect on intracellular levels
of protein-bound glutathione (GSSP) and free glutathione, after 3 (D27) and 10 days (D34) of NVP
treatment; (D) NVP effect on glutathione oxidation (intracellular GSH/GSSG ratio) after 10 days of VP
treat ent (D34). * p < 0.05, ** p < 0.01 and *** p < 0.001 relative to 2D-HLCs. The data are represented
as Mean ± SD, n = 3.
2.3. The Glutathiolomic Profile of 3D Cultures Is Altered upon NVP Exposure in a Time-Dependent Manner
The effect of NVP exposure on the glutathiolomic profile of cells showed no changes on the synthesis
nor catabolism of glutathione in the 3D model (Figure 6A). 2D had a different glutathi ne dynamic with
higher catabolism. However, 3D presented a high reduction of glutathione in both free and protein
bound forms at D34 (Figure 6C). NVP promoted a decrease of GSH intracellular precurs rs and increase
in its main catabolism metabolite CysGly (Figure 6B), which is consistent with a decrease in both free
and protein-bou d intracellular fractions f GSH (Figure 6D), that was not observed in 2D model
here no variatio s were observed.
Summing up, our findings showed that glutathiolomic profile of 3D cultures is altered upon NVP
expos re in a time-depe e t manner characterized by a reducti n in net intracellular glutathione
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availability, a higher excretion of glutathione and a change in glutathione dynamics disfavoring its
GSSP pools.
3. Discussion
The search for physiologically relevant in vitro hepatic models of human origin that reproduce
liver complexity and that allow for long-term studies remains an important topic. Bearing in mind
the need to overcome the interspecies differences (between rat and human) and the low availability of
human hepatocytes, the objective of the present work was to evaluate the usefulness of a human-based
3D in vitro stem cell derived-hepatic model for long-term drug metabolism and bioactivation studies.
Indeed, 2D cultures do not recapitulate the 3D arrangement nor the vascularization typical of the liver
physiological environment [18]. 3D cultures of human or rat primary hepatocytes, as well as of
hepatic cell lines and HLCs have shown their superiority relative to 2D cultures at the functional level,
also allowing long-term cultures [5,6,19–23]. In particular, the organ-on-a-chip technology emerged
as promising in vitro models by offering the possibility of mimicking blood circulation by creating
a laminar fluid flow, seeding high cell densities, mimicking tissue architecture in a three-dimensional
fashion, consuming low cell and reactant amounts and allowing interconnected culture of different cell
types [24,25]. However, until today, few authors performed a thorough study on drug metabolism
in such devices [26,27]. One of the biggest challenges of using organ-on-a-chip technology is still
the high adsorption of small molecules to the microfluidic device materials (e.g., PDMS) requiring
additional studies to allow the comparison with already existing data generated using polystyrene as
material [26,28]. Spheroid based cultures, on the other hand, are quite well characterized and have
the advantage of enabling both miniaturization and higher throughput [1,9,10,19].
Several 3D in vitro liver models have been reported in the literature over the past
years [5,21,23,29–34]. However, a comprehensive and systematic comparison between distinct cell
culture systems that would allow its wide adoption for pharmacological and toxicological applications
is scarce, whereas data from stem cell derived HLCs is even scarcer. Importantly, most hepatic
differentiation protocols do not generate fully mature hepatocytes with respect to a diversity of
mature hepatic functions, including drug metabolizing capacity, albumin production, urea cycle
activity, or glycogen storage ability. In addition, the time in culture is frequently overlooked, despite
the reports supporting that cells need time in culture to mature and re-establish key ultrastructural
and physiological traits [35]. In fact, the comparison of cell culture systems and cell sources is
a challenging task. Cell viability and stability, morphological and architectural features, Phase I
and Phase II metabolic capacity, response to a large panel of well-accepted reference drugs, as well
as the physiological preservation of key metabolic and signaling pathways under long-term hepatic
cultures shall be taken into consideration for pharmacological and toxicological studies. Altogether,
these topics highlight the need for the proper definition of a set of consensus criteria, comprising critical
elements such as cell viability, morphology, functionality and toxicological characterization, as well as
time in culture [3]. It further supports that the choice of reference drugs for showing the relevance of
the cell culture model and of the cell source is neither trivial nor consensual.
NVP was considered as model drug due to its toxicity mechanisms and given that its bioactivation
requires a functional and physiologically relevant cellular model (showing Phase I, II and III activity).
This drug can be bioactivated into the reactive electrophilic metabolites 12-sulfoxy-NVP (stemming from
sulfotransferase-mediated sulfonation of 12-OH-NVP) and NVP-quinone-methide (formed upon NVP
oxidation) (Figure 1). These metabolites have distinct abilities to form covalent adducts with proteins,
which can either lead to toxic effects [36,37] or undergo detoxification via glutathione conjugation [6].
Thus, NVP reactive metabolites can also directly fine-tune glutathione availability and dynamics [7].
The steady state relative proportions of NVP metabolites in clinical, pre-clinical and in vitro
studies differs greatly in the literature (Table 2). Nevertheless, 12-OH-NVP is typically described as
the major NVP metabolite. 3-OH-NVP is consensually the third most detected metabolite, whereas
the 8-OH-NVP is a minor metabolite [14,16] only detected in samples derived from human systems
Int. J. Mol. Sci. 2020, 21, 3998 10 of 18
(Table 2), which is consistent with the low levels of 8-OH-NVP found in this study. In this work,
as well, the most detected metabolite was 2-OH-NVP (~60% at D34), followed by 12-OH-NVP (~27%
at D34), 3-OH-NVP (10–15% at D34) and 8-OH-NVP with a proportion of less than 2% in all conditions.
Concerning the relative proportions of 12-OH-NVP and 2-OH-NVP, and although in our system
the most abundant metabolite was 2-OH-NVP, there was a 3-fold increase of 12-OH-NVP from D27 to
D34 (Figure 4). This result is in accordance with Erickson et al. [16] that showed that the formation
rate of 2-OH-NVP by human CYP3A4/5 in microsomal preparations is ~2-fold higher than that of
12-OH-NVP. The decrease of 2-OH-NVP (2-fold decrease) and increase of 12-NVP-OH (3-fold increase)
Cmax from single dose to steady-state has also been reported in clinical studies [38,39], suggesting
that our data might correspond to the NVP induction period that lasts at least two weeks in vivo [40].
Importantly, the 2-OH-NVP levels in the 3D-HLCs became comparable to those in the 3D-rat hepatocyte
system after 3 days of NVP exposure.
Table 2. Comparison of relative levels (expressed as percentage) of NVP metabolites in clinical,
pre-clinical and in vitro studies.
Study Type Sample 2-OH-NVP * 12-OH-NVP * 3-OH-NVP * 8-OH-NVP * Ref.
Clinical, 2 weeks of NVP treatment Human plasma 13 43 39 2.0 [40]
Clinical, 4 weeks of NVP treatment Human plasma 15 43 42 2.0 [40]
Clinical, Steady state NVP treatment Human urine 23 33 33 1.0 [14]
Clinical, Steady state NVP treatment Human plasma 13 80 6.0 0.0 [41]
Clinical, Steady state NVP treatment Human plasma 16 75 7.0 2.0 [42]
Clinical, Single Dose NVP treatment Human plasma 32 52 16 0.0 [38]
Clinical, Steady state NVP treatment Human plasma 5 51 9 35 [38]
In vitro, spheroids of freshly isolated rat
primary hepatocytes, exposed to NVP
for 11 days
Cell culture
supernatant of rat
hepatocytes
25 57 18 0.0 [6]
In vitro, human cryopreserved
microsomal preparations
Microsomes, reaction
buffer 39 27 27 7.0 [16]
In vitro, HLC spheroids exposed to NVP
for 10 days
Human cell culture
supernatant 60 28 10 2.0
Present
study
* the relative amounts of NVP metabolites were collected from the literature considering total amounts of metabolites,
including Phase II metabolites that were incorporated as their Phase I form.
Regarding Phase II metabolism, the 3D conditions potentiated Phase II enzymes expression
(GSTA1-A2, UGT1A1 and SULT1A1) and activity (SULT and UGT) resulting in higher amounts
of NVP-sulfate and glucuronic acid conjugates. Moreover, due to the relevance of S-conjugation
to the toxicity/detoxification balance, GSTA1-A2 expression levels were quantified and analysed
in the context HLCs’ redox homeostasis and glutathione biosynthesis/degradation, by assessing
HLC’s glutathiolomic profile upon NVP treatment. GSTs (Glutathione-S-transferases) are of major
importance in the liver as a cellular defense mechanism and are responsible for the enzymatic
conjugation with GSH. GSTA1/2 share both the expression and regulation mechanisms and substrates,
and account for 3% of total hepatocyte cytoplasmic proteins [43]. 12-Sulfoxy-NVP and the arene oxide
precursor of 3-OH-NVP are the only metabolites known to form glutathione conjugates [44]. From
those, only the formation of 12-sulfoxy-NVP-derived glutathione adducts have been reported to be
GST-dependent, mediated by GSTA1-1, GSTM1-1 and GSTA3-1 [44]. In this study, NVP induced
GSTA1-A2 in 3D-HLCs but not in 2D-HLCs, which may be a cellular adaptive mechanism for protection
against oxidative stress [39]. Indeed, cytoprotective agents induce GSTA2 and concomitantly activate
the PI3K-Akt/ERK-RSK1-mTOR pathways that in turn activate transcription factors favoring cell
viability [39]. Accordingly, NVP altered our 3D model glutathiolomic profile in a time-dependent way.
The NVP exposure time led to a reduction in net intracellular glutathione availability, a higher excretion
of glutathione, probably in order to supply cysteine to maintain cell viability, and by a change in
glutathione dynamics disfavoring GSSP pools, corroborating a toxic response. Studies are emerging
showing that protein glutathionylation underlies the mechanism and might represent a predictive
marker of drug-induced hepatotoxicity [13,45,46]. These major changes in glutathione net flux were
observed only in 3D-HLCs, corroborating the competence of the cellular model to bioactivate NVP
into its toxic metabolites. This observation and the maintenance of a stable basal glutathiolomic profile
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in the 3D model, supports the suitability of the 3D HLC model to investigate changes in net flux
of glutathione, its availability and dynamics between intracellular pools upon toxic chronic insult.
Moreover, it highlights the relevance of evaluating the global glutathiolomic profile comparing to
GSH/GSSG ratio.
The transport of xenobiotics and its metabolites is as relevant as Phase I and II metabolisms for
assessing drug toxicity profiles. This aspect is often overlooked on HLCs studies. NVP is a MRP-7
(ABCC10) substrate [47] and although there is no report for MRP7 induction by NVP in human
liver, its induction has been observed in in vivo mouse models of cholestasis (lipopolysaccharide
administration and bile duct ligation) revealing its importance on hepatotoxicity [48]. A recent
in vitro study using an organotypic culture of cryopreserved hpHep exposed to supra-therapeutic
concentrations NVP also revealed an increased cholestasis potential of NVP through a transcriptomic
analysis [49]. Our previous transcriptomic study on 2D-HLCs has shown that MRP7 levels in at D34
were closer to hpHep than the expression levels observed in HepG2 and in hnMSCs [4]. In the present
study, we observe that MRP7 gene expression was induced by NVP, but only in 3D-HLCs. Taken
together, our 3D-HLCs were able to show a complete metabolic profile covering all essential process of
drug metabolism.
4. Materials and Methods
4.1. Cell Culture
All culture media and supplements, solvents (all of analytical grade) and other chemicals were
acquired from Sigma-Aldrich (Madrid, Spain) unless specified.
hnMSCs isolated from human umbilical cord stroma were fully characterized and expanded
in Eagle’s minimum essential medium - alpha modification (α-MEM) supplemented with 10% (v/v)
of fetal bovine serum (FBS, Gibco, Paisley, UK) as described previously [50]. For generating HLCs,
a three-step differentiation protocol was applied to hnMSCs cultured in 2D and as 3D spheroids using
ultra-low attachment (ULA, VWR International, Radnor, PA, USA) plates as detailed previously [5].
Briefly, hnMSCs were seeded at a density of 1.5 × 105 cells/cm2 in a rat-tail collagen (0.2 mg/mL)-coated
surface. At day 17 (D17) of differentiation, cells were trypsinized and reinoculated in differentiation
medium (Iscove’s modified Dulbecco’s medium (IMDM) with 8 ng/mL oncostatin M (OSM; Peprotech,
Rocky Hill, NJ, USA), 1 µM dexamethasone, 1% DMSO and 1% insulin-transferrin-selenium solution
(Gibco, Grand Island, NY, USA) at a final concentration of 1.72 µM, 68.75 nM and 38.73 nM, respectively)
containing 20 µM 5-azacytidine and 5% (v/v) FBS into (i) ULA plates (2.5 × 104 cells/mL) to obtain
a 3D spheroid culture or (ii) 2D culture plates pre-coated with collagen (2 × 104 cells/cm2) as
control (Figure 7). Cells were maintained for 24 h and then the medium was replaced by third step
differentiation medium [5]. Medium replacement occurred every 3 days. The cell cultures were
monitored microscopically using phase contrast microscopy (Olympus CK30 inverted microscope,
Tokyo, Japan).
For NVP (Cipla, Mumbai, India) treatment, a stock solution was prepared in DMSO
at a concentration of 150 mM. For cell incubation, NVP was diluted in complete medium to a final
concentration of 300 µM. This concentration is considered non-cytotoxic and supra-therapeutic
and was chosen according to values previously described in the literature [6,8,51–53]. HLCs at D24 of
the differentiation protocol were exposed during 3 (D27) and 10 days (D34), whereas hnMSCs were
treated for 72 h (Figure 7). Cell culture volume was adjusted in order to obtain a volume per cell
equivalent in both 3D and 2D systems. Complete medium without NVP, as well as complete medium
with solvent (supplemented with additional 0.2% DMSO) and without NVP were used as negative
and solvent controls, respectively.
Images were acquired using Moticam 5.0 (Motic, Barcelona, Spain) and recorded with Motic
Images Plus 2.0 software. The spheroid diameter was evaluated every 3 days [50].
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The cell number was calculated as described previously [19,21]. The protein content of the cell
pellet samples from 3D and 2D cultures was determined using the BCA protein assay kit (Millipore,
Burlington, MA, USA) according to manufacturer’s instructions.
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4.2. Nevirapine Cytotoxicity
NVP cyt toxicity was assessed usi g the MTS cell viability assay (Promega, Madison, WI, USA),
acc rdi g to the manufacturer’s instructions. NVP conc ntrations ranging from 25 to 2000 µM were
tested in HLCs. Briefly, HLCs w re s eded in 100 µL of cultur m dium at a density of 6400 per well in
96-well coll ge -coated plates. Cultures were then incubated for 72 h. Three independent experiments
wer p rformed. The results showed no differenc s between the NVP-exposed cells and non-ex osed
cells up to 1000 µM indicating no cytotoxic effects of either NVP or its metabolites during th whole
culture tim for the conc tration of 300 µM.
4.3. Biotransformation Activity
CYP enzyme activity was measured by means of 7-ethoxycoumarin-O- eethylase (ECOD) activity
(covering CYP2B6, 1A1/2 and 2E1) [17] and P450-GloTM assays (Promega) and UGT a tivity by means
of 4-methylumbelliferone conjugation as described previously [4]. The thermos able SULT1A1 activity
was assessed in cell homogenates from both 2D and 3D cultures, obtained by sonication of cell pellets,
containing ~7 × 104 cells, suspended in 200 µL of sonication buffer (10 mM triethanolamine at pH
7.4, with 250 mM sucrose and 5 mM β-mercaptoethanol). Sonication procedures were performed
on ice. SULT1A1 activity was assessed using the 2-naphthol (2-NAF) sulfonation assay in cell
homogenates as previously described [6]. The reaction mixture contained 50 mM phosphate buffer
(pH 7.5), 5 mM MgCl2, 500 µM EDTA, 20 µM 3′-phosphoadenosine-5′-phosphosulfate (PAPS), 5 mM
potassium p-nitrophenyl sulfate (KNPS) and 100 µM of 2-naphthol (Merck, Darmstad, Germany).
An effective PAPS-regenerating system was obtained with the addition of p-nitrophenyl sulfate.
SULT1A1 catalyzes the synthesis of 2-naphthyl sulfate from 2-NAF and PAPS, while regeneration of
the PAPS cofactor produces p-nitrophenol. The measurement of p-nitrophenol absorbance at 405 nm
is, therefore, an indirect measurement of sulfotransferase activity. A calibration curve was generated
with p-nitrophenoland the absorbance was registered at 405 nm (SPECTROstar Omega, BMG Labtech,
Ortenberg, Germany) after a 5-h incubation at 37 ◦C in a humidified atmosphere.
The ECOD, CYP3A4/5, UGT and SULT1A1 activities were normalized to incubation time (h)
and cell number (106 cells) and expressed as fold induction in NVP-treated cultures relative to
non-treated cultures. The data for the activity normalized to incubation time (h) and cell number
(106 cells) is presented in Supplementary Figure S1.
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4.4. Quantification of Nevirapine Metabolites
Supernatants from 3D and 2D cell cultures were collected (triplicates) on D27, D31 and 34
of the differentiation and treated separately. The data for D31 is presented in Supplementary
Figure S2. Phase I and Phase II NVP metabolites were analyzed and quantified by HLPC as described
previously [41]. Briefly, for the quantification of Phase I and Phase II NVP metabolites, 15 mL
of cell culture supernatants were incubated for 24 h at 37 ◦C in the absence (unconjugated/free
metabolites) or presence of either sulfatase (type H-1 from Helix pomatia, E.C. 3.1.6.1, 100 U/mL,)
and d-saccharic acid 1,4-lactone (4 mg/mL), for the detection of free metabolites plus sulfate
conjugates [54], or β-glucuronidase (type VII-A from E. coli, E.C. 3.2.1.31, 100 U/mL), for the detection
of free metabolites plus glucuronic acid conjugates [55]. The pH of all samples was readjusted to
7.0 before extraction of the free metabolites with dichloromethane (2 × 15 mL). Upon evaporation,
the organic extracts were dissolved in 150µL H2O/methanol (1:1) and analyzed on an Agilent 1100 Series
HPLC-UV system (Agilent Technologies Inc., Santa Clara, CA, USA) as described in Marinho et al. [41].
The metabolite levels were normalized to the cell number and expressed as ng/106 cells.
4.5. Gene Expression
RNA isolation was performed using Trizol® (Ambion, Inc., Austin, TX, USA). RNA was quantified
prior to cDNA synthesis as previously described. cDNA synthesis was performed from 0.5 µg of
RNA using a commercially available kit (NZYTech, Lisbon, Portugal) and quantitative real-time PCR
(qPCR) was performed using PowerUp™ SYBR® Green Master Mix (Applied Biosystems®/ Life
Technologies, Austin, TX, USA), according to the manufacturer’s instructions. A final reaction volume
of 15 µL, with 1 µL of template cDNA and 0.1 µM of forward and reverse primers (Table 3) was used
and the reaction was conducted in the ABI7300 Real-time PCR system (Applied Biosystems®/Life
Technologies, Carlsbad, CA, USA). The amplification of cDNA consisted of a denaturation step at 95 ◦C
for 10 min, 40 cycles of denaturation at 95 ◦C for 15 s, annealing at 60 ◦C for 1 min and extension
at 72 ◦C for 30 s. As a quality and specificity measurement, a dissociation stage was added to determine
the melting temperature in all runs. The comparative Ct method (2−∆∆CT) was used to quantify
the amount of target genes, normalized to the reference gene β-ACTIN and relative to non-NVP-treated
cells, unless otherwise stated. The efficiency of each PCR reaction was estimated from a set of serially
diluted cDNA control solutions from in order to construct a standard curve (1, 10−1, 10−2) for each
gene, considering efficiencies between 1.8–2.2.
4.6. Glutathiolomic Profiling
Both cells (intracellular fraction) and cell supernatants (extracellular fraction) were collected
from 2D and 3D cultures upon exposure or non-exposure of NVP. The extracellular (cell culture
supernatants) and intracellular (cell lysates) fractions were collected at D27 and 34 of the differentiation
protocols. The samples were processed and the glutathiolomic profile was measured as previously
described [59], comprising the levels of cysteine (Cys), γ-glutamylcysteine (GluCys), cysteinylglycine
(CysGly) and glutathione. The glutathiolomic profile comprises an integrated assessment of net
availability and dynamics of glutathione in cell. In addition to the commonly used approach of
evaluating reduced (GSH)/oxidized (GSSG) glutathione ratio, a complete assessment of glutathione
net flux was performed. This included the clarification of total availability, distribution between
intracellular pools, synthesis and degradation. For that, total (free + protein bound) intracellular
glutathione availability was measured. Also, we addressed the dynamics of its intracellular distribution
between pools: free (reduced and oxidized) and protein bound through the quantification of each
fraction. Finally, we measured anabolic (intracellular GluCys/Cys ratio) and catabolic (extracellular
CysGly/GSH ratio) activities for glutathione. Briefly, for glutathiolomic profiling cells were collected
and immediately sonicated in 200 µL of ice-cold phosphate-buffered saline with 1% Triton. The amount
of total thiols was obtained by reducing the sulfhydryl groups with tris(2-carboxyethyl)phosphine
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hydrochloride (TCEP; 100 g/L). After a 30 min incubation at room temperature, the samples were
treated with trichloroacetic acid (TCA; 100 g/L) containing EDTA (1 mM), for protein precipitation.
After centrifugation (13,000× g, 10 min, 4 ◦C), the supernatant was collected for derivatization of the free
sulfhydryl groups. Derivatization was performed with 7-fluorobenz-2,1,3-oxadiazole-4-sulfonic acid
ammonium salt (SBD-F) at 1 g/L in 125 mM sodium tetraborate buffer (pH 9.5) with 4 mM EDTA
and 1.55 M NaOH, at 60 ◦C for 1 h, protected from light. Finally, a volume of 30 µL was analyzed by
HLPC-FD. The quantification of the free forms was performed in cells and in cell culture supernatants.
The latter were collected on ice and centrifuged for 5 min at 10,000× g at 4 ◦C for cell debris removal,
whereas cell samples were prepared as abovementioned. Samples were then submitted to protein
precipitation with TCA, with subsequent centrifugation (13,000× g, 10 min, at 4 ◦C) and reduced with
TCEP for RLMWT quantification or incubated with reverse osmosis water to obtain the naturally
reduced RSH fraction. After 30 min incubation at room temperature, the previously described
derivatization protocol was followed. HPLC-FD analysis was performed on a Shimadzu LC-10AD
VP system (Shimadzu Scientific Instruments Inc., Columbia, MD, USA) using a reversed-phase C18
LiChroCART 250-4 column (LiChrospher 100 RP-18, 5 µm, VWR International, Radnor, PA, USA),
at 29 ◦C with a fluorescence detector (λEx: 385 nm/λEm: 515 nm). The mobile phase consisted of
100 mM sodium acetate buffer (pH 4.5) and methanol [98:2 (v/v)]. The analytes were separated in
isocratic elution mode for 22 min, at a flow rate of 0.6 mL/min. The data expressed as average ± SD
were normalized with cell number and represented as nmol/106 cells for non-treated cells and as fold
induction in NVP-treated cultures relative to non-treated cultures.
Table 3. Primers used for qRT-PCR characterization of NVP treated and non-treated HLCs, hnMSCs.
Primers Reference
ACTB_F CATGTACGTTGCTATCCAGGC PrimerBank ID 4501885a1 [56]
ACTB_R CTCCTTAATGTCACGCACGAT
CYP3A4_F ATTCAGCAAGAAGAACAAGGACA [57]
CYP3A4_R TGGTGTTCTCAGGCACAGAT
CYP2B6_F TTCCTACTGCTTCCGTCTATCAAA [58]
CYP2B6_R GTGCAGAATCCCACAGCTCA
CYP2D6_F TGGCAAGGTCCTACGCTTC [58]
CYP2D6_R GCCACCACTATGCACAGGTT
SULT1A1_F CGGCACTACCTGGGTAAGC PrimerBank ID: 29540539a1 [56]
SULT1A1_R CACCCGCATGAAGATGGGAG
UGT1A1_F TGACGCCTCGTTGTACATCAG [58]
UGT1A1_R CCTCCCTTTGGAATGGCAC
GSTA1-A2_F TGCAACAATTAAGTGCTTTACCTAAGTG [58]
GSTA1-A2_R TTAACTAAGTGGGTGAATAGGAGTTGTATT
MRP7_F TGGCACATTCCCCTCATGG [58]
MRP7_R CCACAACACGGTCAGCACTA
4.7. Statistical Analysis
Data comparison was performed by two-way ANOVA analyses using GraphPad Prism version
6.0 (GraphPad Software, Inc., San Diego, CA, USA). Differences were considered statistically significant
for p < 0.05.
5. Conclusions
The work herein presented shows for the first time that a 3D-HLC human model is able to
metabolize NVP by correctly displaying its biotransformation profile, as well as by mimicking
the auto-induction processes observed in patients treated with NVP-based regimens. Importantly, to
our knowledge, this also the first report where a similar pattern regarding metabolites’ quantification
is shown in human stem cell-derived HLCs. Moreover, an additional innovative aspect of this work,
the glutathiolomic analysis, reflected the higher glutathione production in 3D cultures, which together
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with a more effective glucuronic acid conjugation also suggests a higher ability to scavenge reactive
species in the 3D-HLCs compared to the 2D model. Altogether, these observations reinforced
the 3D-HLCs biotransformation competence over the 2D model. In summary, this study constitutes
a step forward in the development of human physiologically relevant mechanistic models for drug
testing where an integrated approach might guide risk mitigation for early drug safety assessments
during drug development.
Supplementary Materials: The following are available online at http://www.mdpi.com/1422-0067/21/11/3998/s1,
Figure S1: Phase I and Phase II enzymatic induction in 3D- and 2D-HLCs non-treated and after 3 (D27) and 10
days (D34) of NVP treatment., Figure S2: Levels of NVP Phase I and II metabolites in 3D-HLCs (top) and 2D-HLCs
(bottom) after 3 (D27), 7 (D31) and 10 days (D34) of NVP treatment.
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